Eikon Therapeutics has disclosed its intentions to generate $273.5 million from its upcoming initial public offering (IPO) as it prepares to go public after announcing its plans earlier this year. The biotechnology company, which specializes in oncology, is set to offer 17,648,000 shares at a price of $17 each, according to a filing made with the Securities and Exchange Commission. Should shares be priced at the maximum indicated amount of $18, Eikon stands to raise approximately $317.7 million.
In addition to the initial offering, Eikon’s underwriters have a 30-day option to purchase up to an additional 2,647,200 shares, potentially expanding the total capital raised in the IPO.
If Eikon successfully completes this offering, it will become the second biotech firm to launch an IPO in 2023, following Aktis Oncology.
Founded in 2021 and led by former Merck & Co. executive Dr. Roger Perlmutter, Eikon has made a name for itself in the fundraising arena. The company raised an impressive $517 million in 2022, followed by $106 million in 2023 and an additional $350 million earlier this year.
Eikon is targeting a listing on the Nasdaq to support its diverse portfolio of four clinical-stage candidates. Leading its pipeline is EIK1001, an immune modulator that acts on toll-like receptors 7 and 8, which the company acquired from Seven and Eight Biopharmaceuticals. EIK1001 is currently undergoing phase 2/3 trials in conjunction with Keytruda for treating advanced melanoma and is also being evaluated for non-small cell lung cancer.
Acquired from Chinese biotech Impact Therapeutics, Eikon is developing two PARP1 inhibitors, EIK1003 and EIK1004, which are in phase 1/2 studies for various cancers, including ovarian, breast, prostate, and pancreatic. Notably, EIK1004 is also being tested for its efficacy against brain metastases and primary brain malignancies, owing to its capability to penetrate the blood-brain barrier.
The fourth candidate in Eikon’s pipeline is an in-house WRN helicase inhibitor, EIK1005, which is in phase 1/2 development for solid tumors.
Despite having raised over $1 billion to date, Eikon has not been immune to the challenges faced by the biopharmaceutical industry. In May 2025, the company made the difficult decision to lay off nearly 15% of its workforce, attributing this action to cuts in government funding.
